Abstract 210P
Background
Vascularization is known to be linked to tumour growth. We explored the potential of automated lung tumour vascularity assessment as risk factor for landmark survival.
Methods
131 CT scans from the NSCLC Radiogenomics dataset were evaluated. All patients underwent surgery, with or without other therapies. Primary lung tumour (PLT) is segmented by a radiologist. Vessels segmentation (arteries and veins) is performed by an in-house deep learning segmentation model. Vascularity features extracted for the PLT include: amount of blood vessel connections, % of the tumour surface connected to vessels (%area), and basic statistics on the surface area of the connections. A generalized linear model (GLM) to predict landmark survival was trained with these features, tumour volume, and clinical factors. Stepwise feature reduction was performed to arrive to the final model. We present the odds ratio (OR) as well as a combined risk score for the remaining independent predictors.
Results
Landmark survival was reached for 86/131 (66%) patients. GLM analysis showed 4 independent risk factors related to landmark survival: %area (OR= 1.69 for >2.5%), age (OR=1.57 for >70 years), gender (OR=2.10 for male) and radiation therapy (OR=1.51 for yes). Smoking status and tumor volume were not retained in the final model. We also showed that risk of dying before landmark survival increased with increased number risk factors (0%, 18%, 40%, 48% and 100% for 0, 1, 2, 3, 4 risk factors, respectively).
Conclusions
Lung tumour vascularity is an independent risk factor for landmark survival. We showed an approach were it can be used as additional prognostic factor to inform clinical decision making and therapy planning.
Clinical trial identification
Editorial acknowledgement
Fabio Bottari, PhD, of Radiomics for providing medical writing support in accordance with Good Publication Practice ( GPP 2022) guidelines.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blistein, F. Belmans, S. Goffart, L. Libert, R. Narasimhan, A. Corsi: Financial Interests, Personal, Full or part-time Employment: Radiomics. W. Vos: Financial Interests, Personal, Leadership Role: Radiomics. M. Occhipinti: Financial Interests, Personal, Financially compensated role: Radiomics. All other authors have declared no conflicts of interest.
Resources from the same session
217P - Clinical and molecular features of PTCH1 mutant in solid tumors
Presenter: Xuezheng Li
Session: Poster session 01
218P - Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Presenter: WON SUK LEE
Session: Poster session 01
219P - Multicentric evaluation of amplicon-based next-generation sequencing solution for local comprehensive molecular tumor profiling
Presenter: Eloisa Jantus Lewintre
Session: Poster session 01
220P - Biomarker of blood age and inflammation in older cancer patients might predict outcome
Presenter: Marcus Vetter
Session: Poster session 01
221P - Peripheral T cell activation phenotype predicts clinical outcomes of atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
Presenter: Chan Kim
Session: Poster session 01
222P - Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer
Presenter: Natalie Cook
Session: Poster session 01
223P - Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
Presenter: Gianluca Mauri
Session: Poster session 01
224P - Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
Presenter: Afaf Abed
Session: Poster session 01
225P - Utility of next-generation sequencing (NGS) in patients with advanced cancer in a low-middle income country
Presenter: Milton Lombana Quinonez
Session: Poster session 01
226P - LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial
Presenter: Jiangfeng Ye
Session: Poster session 01